Login to Your Account


Maximizing returns on proof of concept oncology trials

By Brian Orelli
Contributing Writer

Monday, April 14, 2014

SAN DIEGO – When designing phase II proof of concept trials, companies want to maximize the chance of seeing a signal. Avoiding so-called type III errors – trials that would have been successful but were never performed – leads to a "no drug left behind" mentality, Cong Chen, director of biostatistics and research decision science at Merck & Co. Inc. told the audience during a panel at the American Association for Cancer Research meeting last week.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription